Literature DB >> 16322563

Human soluble epoxide hydrolase: structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids.

German A Gomez1, Christophe Morisseau, Bruce D Hammock, David W Christianson.   

Abstract

X-ray crystal structures of human soluble epoxide hydrolase (sEH) complexed with four different dialkylurea inhibitors bearing pendant carboxylate "tails" of varying length have been determined at 2.3-3.0 A resolution. Similarities among inhibitor binding modes reinforce the proposed roles of Y381 and/or Y465 as general acids that protonate the epoxide ring of the substrate in concert with nucleophilic attack of D333 at the electrophilic epoxide carbon. Additionally, the binding of these inhibitors allows us to model the binding mode of the endogenous substrate 14,15-epoxyeicosatrienoic acid. Contrasts among inhibitor binding modes include opposite orientations of inhibitor binding in the active-site hydrophobic tunnel. Alternative binding orientations observed for this series of inhibitors to human sEH, as well as the binding of certain dialkylurea inhibitors to human sEH and murine sEH, complicate the structure-based design of human sEH inhibitors with potential pharmaceutical applications in the treatment of hypertension. Thus, with regard to the optimization of inhibitor designs targeting human sEH, it is critical that human sEH and not murine sEH be utilized for inhibitor screening, and it is critical that structures of human sEH-inhibitor complexes be determined to verify inhibitor binding orientations that correlate with measured affinities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322563      PMCID: PMC1762130          DOI: 10.1110/ps.051720206

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  34 in total

1.  Detoxification of environmental mutagens and carcinogens: structure, mechanism, and evolution of liver epoxide hydrolase.

Authors:  M A Argiriadi; C Morisseau; B D Hammock; D W Christianson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

2.  An extensively modified version of MolScript that includes greatly enhanced coloring capabilities.

Authors:  R M Esnouf
Journal:  J Mol Graph Model       Date:  1997-04       Impact factor: 2.518

3.  Binding of alkylurea inhibitors to epoxide hydrolase implicates active site tyrosines in substrate activation.

Authors:  M A Argiriadi; C Morisseau; M H Goodrow; D L Dowdy; B D Hammock; D W Christianson
Journal:  J Biol Chem       Date:  2000-05-19       Impact factor: 5.157

4.  Mechanism of microsomal epoxide hydrolase. Semifunctional site-specific mutants affecting the alkylation half-reaction.

Authors:  L T Laughlin; H F Tzeng; S Lin; R N Armstrong
Journal:  Biochemistry       Date:  1998-03-03       Impact factor: 3.162

5.  Structural refinement of inhibitors of urea-based soluble epoxide hydrolases.

Authors:  Christophe Morisseau; Marvin H Goodrow; John W Newman; Craig E Wheelock; Deanna L Dowdy; Bruce D Hammock
Journal:  Biochem Pharmacol       Date:  2002-05-01       Impact factor: 5.858

6.  Cytochrome P450 2C is an EDHF synthase in coronary arteries.

Authors:  B Fisslthaler; R Popp; L Kiss; M Potente; D R Harder; I Fleming; R Busse
Journal:  Nature       Date:  1999-09-30       Impact factor: 49.962

7.  Mechanism of mammalian soluble epoxide hydrolase inhibition by chalcone oxide derivatives.

Authors:  C Morisseau; G Du; J W Newman; B D Hammock
Journal:  Arch Biochem Biophys       Date:  1998-08-15       Impact factor: 4.013

8.  Molecular and biochemical evidence for the involvement of the Asp-333-His-523 pair in the catalytic mechanism of soluble epoxide hydrolase.

Authors:  F Pinot; D F Grant; J K Beetham; A G Parker; B Borhan; S Landt; A D Jones; B D Hammock
Journal:  J Biol Chem       Date:  1995-04-07       Impact factor: 5.157

9.  Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility.

Authors:  In-Hae Kim; Christophe Morisseau; Takaho Watanabe; Bruce D Hammock
Journal:  J Med Chem       Date:  2004-04-08       Impact factor: 7.446

10.  Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors.

Authors:  W B Campbell; D Gebremedhin; P F Pratt; D R Harder
Journal:  Circ Res       Date:  1996-03       Impact factor: 17.367

View more
  38 in total

1.  Soluble epoxide hydrolase as an anti-inflammatory target of the thrombolytic stroke drug SMTP-7.

Authors:  Naoki Matsumoto; Eriko Suzuki; Makoto Ishikawa; Takumi Shirafuji; Keiji Hasumi
Journal:  J Biol Chem       Date:  2014-10-31       Impact factor: 5.157

Review 2.  Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.

Authors:  Hong C Shen; Bruce D Hammock
Journal:  J Med Chem       Date:  2012-01-17       Impact factor: 7.446

3.  Pseudomonas aeruginosa Cif defines a distinct class of α/β epoxide hydrolases utilizing a His/Tyr ring-opening pair.

Authors:  Christopher D Bahl; Dean R Madden
Journal:  Protein Pept Lett       Date:  2012-02       Impact factor: 1.890

4.  Design, synthesis and evaluation of non-urea inhibitors of soluble epoxide hydrolase.

Authors:  Stevan Pecic; Shi-Xian Deng; Christophe Morisseau; Bruce D Hammock; Donald W Landry
Journal:  Bioorg Med Chem Lett       Date:  2011-10-28       Impact factor: 2.823

5.  Evolution of a Catalytic Mechanism.

Authors:  Alissa Rauwerdink; Mark Lunzer; Titu Devamani; Bryan Jones; Joanna Mooney; Zhi-Jun Zhang; Jian-He Xu; Romas J Kazlauskas; Antony M Dean
Journal:  Mol Biol Evol       Date:  2015-12-16       Impact factor: 16.240

6.  Solid-phase combinatorial approach for the optimization of soluble epoxide hydrolase inhibitors.

Authors:  Sung Hee Hwang; Christophe Morisseau; Zung Do; Bruce D Hammock
Journal:  Bioorg Med Chem Lett       Date:  2006-09-01       Impact factor: 2.823

7.  Outliers in SAR and QSAR: is unusual binding mode a possible source of outliers?

Authors:  Ki Hwan Kim
Journal:  J Comput Aided Mol Des       Date:  2007-03-03       Impact factor: 3.686

8.  Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities.

Authors:  Takeo Kasagami; In-Hae Kim; Hsing-Ju Tsai; Kosuke Nishi; Bruce D Hammock; Christophe Morisseau
Journal:  Bioorg Med Chem Lett       Date:  2009-01-27       Impact factor: 2.823

9.  Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs.

Authors:  Hsing-Ju Tsai; Sung Hee Hwang; Christophe Morisseau; Jun Yang; Paul D Jones; Takeo Kasagami; In-Hae Kim; Bruce D Hammock
Journal:  Eur J Pharm Sci       Date:  2010-03-30       Impact factor: 4.384

10.  Effect of soluble epoxide hydrolase polymorphism on substrate and inhibitor selectivity and dimer formation.

Authors:  Christophe Morisseau; Aaron T Wecksler; Catherine Deng; Hua Dong; Jun Yang; Kin Sing S Lee; Sean D Kodani; Bruce D Hammock
Journal:  J Lipid Res       Date:  2014-04-27       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.